Ventyx Biosciences, Inc.

Ventyx reported first-quarter 2024 R&D expense of $33.7 million, down from $35.4 million a year earlier, and G&A expense of $8.0 million versus $7.1 million in Q1 2023. Net loss was $38.6 million compared with $38.9 million in the prior-year quarter. Cash, cash equivalents and marketable securities were $302.6 million as of March 31, 2024. Net cash used in operating activities was $47.6 million, and management said current cash is sufficient to support planned operations into at least the second half of 2026. No next-quarter or full-year revenue/EPS guidance was given.

Raju Mohan framed the quarter around pipeline progress rather than near-term commercial metrics, emphasizing that VTX3232 and VTX2735 both generated data that strengthen the company’s NLRP3 strategy. He repeatedly described VTX3232 as a potential best-in-class, Phase II-ready CNS-penetrant asset and highlighted planned follow-on studies in Parkinson’s disease and obesity. For VTX002 and VTX958, his tone was constructive and forward-looking, pointing to Phase III readiness for VTX002 and completion of enrollment for VTX958.

Martin Auster highlighted a relatively stable loss profile year over year, with R&D down to $33.7 million from $35.4 million and net loss roughly flat at $38.6 million versus $38.9 million. He said operating cash use of $47.6 million was higher than operating expenses because of changes in prepaid and accrued items, but expected quarterly operating expenses and cash flows to decline in Q2 and remain lower through the rest of 2024 as VTX958 psoriasis and psoriatic arthritis wind-down work finishes. He reiterated that $302.6 million of cash, cash equivalents and marketable securities should fund operations into at least the second half of 2026.

Analysts focused heavily on VTX3232’s obesity and Parkinson’s programs, asking what human signal would matter in short trials, what toxicology package supports the next studies, and how the program compares with other NLRP3 approaches. Management said the current tox package supports a 28-day study and later chronic studies, and stressed that the mouse work is a proof-of-concept exercise rather than a way to pick human dose. Questions on VTX002 centered on partnership interest and the FDA End-of-Phase 2 meeting; management said the meeting was “very successful” and that it is actively pursuing pharma interest without sharing specifics. On VTX2735, analysts asked about timelines and fit in recurrent pericarditis/MACE, and management said planning is the main gating step and described recurrent pericarditis as a niche orphan setting where an oral NLRP3 inhibitor could fit well.